便calprotectin对于性结肠炎中组织学缓解的预测准确性
Arshdeep Singh1, Arshia Bhardwaj1, Riya Sharma2
1Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, India.
Intestinal research
|November 11, 2024
概括
便calprotectin (FC) 准确地预测了性结肠炎 (UC) 患者的组织学缓解. 较低的FC值提高了预测准确度,可能减少对结肠镜检查的需要,以评估UC疾病活性.
科学领域:
- 胃肠病学 胃肠病学
- 炎症性肠道疾病研究研究
- 临床试验分析
背景情况:
- 精确评估性结肠炎 (UC) 疾病活性对于有效的患者管理至关重要.
- 临床,内镜和组织学参数用于衡量UC严重程度.
- 了解这些措施之间的相关性对于优化治疗策略至关重要.
研究的目的:
- 评估性结肠炎 (UC) 疾病活动的临床,内镜和组织学标志物之间的相关性.
- 评估UC不同组织学评分系统之间的一致性.
- 确定便calprotectin (FC) 对UC患者内镜和组织学缓解的预测准确度.
主要方法:
- 一项涉及347名UC患者的研究评估了临床,生化,内镜和组织学疾病活性.
- 组织学数据使用盖博斯评分 (GS),连续GS,南希指数 (NI) 和罗巴特组织病理学指数 (RHI) 进行分析.
- 评估了便calprotectin (FC) 在实现内镜和组织学缓解方面的预测价值.
主要成果:
- 在UC疾病活动的临床,内镜和组织学测量之间观察到适度的相关性.
- 组织学评分系统 (GS,连续GS,NI,RHI) 在确定缓解与活动方面表现出强烈的一致性.
- 在150μg/g以下的便calprotectin (FC) 水平显示,预测内镜缓解的准确性>70%,组织学缓解的准确性≥80%,在较低的值 (<100μg/g) 时的准确性更高.
- 在活检样本中,高FC水平与炎症透物相关.
结论:
- 便calprotectin (FC) 作为一个可靠的非侵入性预测器,在性结肠炎 (UC) 患者的组织学缓解.
- 格博斯评分 (GS),连续GS,南希指数 (NI) 和罗巴特组织病理指数 (RHI) 在UC评估中表现相似.
- FC可以帮助分层UC患者,这些患者可能需要结肠镜检查以评估内镜和组织学缓解.
相关概念视频
01:30Serum Laboratory Studies, Stool Test, Breath Test
316
Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...
316
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
319
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
319
01:29Drugs for Treatment of Ulcerative Colitis in IBD
120
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
120
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
143
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
143